These novel therapies , Semaglutide , represent a remarkable advancement in managing metabolic dysfunction and conceivably other ailments . They are classified as GLP-1 receptor stimulators, signifying they to emulate the natural GLP-1 peptide, enhancing insulin release and lowering hunger . Although Retatrutide every functions relatively similarly